Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. - Wikidata - awgldk - TriplyDB

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

http://www.wikidata.org/entity/Q33399238

about

Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.Cellular immune dysfunction in immune thrombocytopenia (ITP).Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.IVIG regulates the survival of human but not mouse neutrophils.Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor.Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.Production of α2,6-sialylated IgG1 in CHO cells Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.Identification of novel plasma glycosylation-associated markers of aging.Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.Mechanisms and potential therapeutic targets in allergic inflammation: recent insights.Review: intravenous immunoglobulin and B cells: when the product regulates the producer.Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.IVIG-mediated effector functions in autoimmune and inflammatory diseases.The Emerging Importance of IgG Fab Glycosylation in Immunity.Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Immunoglobulins: current understanding and future directions.Will sialylation change intravenous immunoglobulin therapy in the future?Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice.Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.Effects of Acyclovir and IVIG on Behavioral Outcomes after HSV1 CNS Infection.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.

P2860

Q26781290-6A550291-0D69-49D7-A871-AE8B517CB58C Q26864907-0F87824A-2BBB-4465-BABF-2E1BB7B7545D Q28069362-CF5BAD91-D0C0-4479-9AE2-A520263289BD Q28728886-024D2B76-A074-44CC-A7ED-4B6DA0A0E77B Q30834514-12ADEA0D-AB7B-4442-86EF-AD06B458020E Q33401630-3179C695-2755-47AC-90EF-1C1F1E05DFD2 Q33409710-A5D3CEC5-1B0A-42A6-BC17-9210DD2A6664 Q33415298-FA60B8BE-5B6B-4A54-AA61-B54AE0E2AF97 Q33419269-FFAEE758-0C92-4EA4-AD4E-7725AA01C0E9 Q33420853-DF63B655-1918-477A-BE3F-35B15D428A6A Q33422858-CD6E18BD-2F5C-446F-9712-ABAA3DF707F2 Q33683531-5A8CB0D8-4BBA-4B6E-90CB-629A818867FF Q33981829-ADA9F29B-20F5-4498-94A1-60C4848B7C2A Q35590264-BFF10ADF-4A9C-4D13-BEB7-0C3319225726 Q36213335-0C4186FC-B4E6-4274-91E2-193A89B1AE77 Q36484438-B14C9F83-6606-418F-A6A4-36C049B837F1 Q36768842-3E10C3A3-8EF7-466D-AB13-4FA59EF4287B Q36946538-6218520C-7F15-4797-8E13-9922F1F6F553 Q37732919-78DF8594-9214-4E9C-BDC1-27DC4E5DE6D0 Q38117686-BB8F8030-1C24-4D9B-9F1C-3492FE7CA76E Q38161574-B8BAB526-950A-423E-B2E3-C2823CDA0A49 Q38258905-979DD8AB-0B13-4C7B-A339-47B18096DFAA Q38344833-86EC31F8-985B-4DC0-B693-1FF32FB52776 Q38478867-4B238ADB-B449-4411-9782-0FCBD919F185 Q38699812-2EF72294-1115-4A91-BD53-B16F9ABC4BE7 Q38724772-35BE5B1E-EE37-4B1B-A782-EA02920E6C24 Q38820288-60D87C6C-2ECD-44C2-8199-DC355FDB1BF5 Q38828582-2AFE6041-78B3-4EA8-A5D8-8433FDF67B28 Q39062945-842C44DD-9B09-46B3-AA35-03B6A4045432 Q39067335-E9995A9F-A9E8-4CFE-BDDF-CA3AF9F8A52E Q39067348-236612BC-4DA9-483E-8D0D-10C2408317D3 Q39361301-6ABC4FF5-5199-4252-8C85-00B909434D92 Q39729881-91EE021C-4BFD-4389-8430-376A8851F027 Q40108236-EACA2CE9-D2BA-4C15-AF27-034A3AEA651E Q42375731-AB0C4280-0304-4BCF-891D-3072BAAAA086 Q45422267-851723C8-AD52-4C25-8AD4-84ED380AB6E4 Q47550160-3D868A0E-9A3F-4386-8F7E-48792AD6A80F Q47804590-F76DBC1E-A393-4371-9B2E-2EA93AFD0200 Q50193260-2C75C7D9-D335-4836-8090-E713A2CA0B3E Q52358342-87BD3B98-0AA5-4B98-8C5D-BEEF3F32882E

P2860

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

http://www.wikidata.org/entity/Q33399238

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@ast

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@en

type

label

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@ast

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@en

prefLabel

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@ast

Sialylation-independent mechan ...... ing intravenous gammaglobulin.

@en

P1433

Q33399238-48B405C8-FE26-4590-A4DF-3B9434139B5B

P1476

Q33399238-1F27D56A-39E8-4DC8-921F-88D4DCDEED17

P2093

Q33399238-31164554-8B9C-4391-8390-4CFCD41A6050

Q33399238-534E856A-8D5B-4F2D-B961-624F85292FBB

Q33399238-561EAA62-755D-45DE-A713-EF9CEAF2A3E2

Q33399238-61A0FF50-EB46-4A18-AD2F-74640B09DE34

Q33399238-FF3299F0-6C12-45CA-8C5A-634ACBC92EDE

P2860

Q33399238-081A2B43-3A46-43A0-A256-2E9BF14D0477

Q33399238-0A95DECF-620D-4580-9131-7077EC5ED8A1

Q33399238-10101047-CA99-465A-9B68-C7C096EEEFAB

Q33399238-21D1E058-CAB1-44A9-8F41-8CFA39921020

Q33399238-233FF0D0-D11E-4852-8A75-0149BBCEA7EE

Q33399238-2C3BA832-3579-4299-B526-457D400864CD

Q33399238-32FD3210-CF4E-428D-959F-587B0E19A042

Q33399238-3414646F-87D5-4DD7-A792-A933BCF9786D

Q33399238-3C3D381D-9538-4381-9573-DF9DAD50060B

Q33399238-3E6FED79-F11C-4241-8AB2-A865A4703E1C

P304

Q33399238-771B6CC7-9383-4B7E-975D-11E5EA11FFD9

P31

Q33399238-6239B994-13C1-4655-BDB6-B385130CC30B

P356

Q33399238-229F85A7-2EA5-45A2-9FDB-D4F31142D6D5

P433

Q33399238-AFA1374F-246E-45AC-AABA-F3AD1A085CC8

P478

Q33399238-02C3C79F-258C-45F3-B980-059463807818

P50

Q33399238-E5DE061A-D494-41D0-BA99-319F1533244F

P577

Q33399238-C018E7B9-3816-4D25-BCF1-F60279437109

P5875

Q33399238-BF384DDC-1ECC-46C3-9C80-8868362BF702

P698

Q33399238-F7BF569D-7D0A-4B40-999F-371C730C6373

P921

Q33399238-AEE73892-6A11-4B07-A429-0FF416011F11

P356

J.1537-2995.2011.03517.X

P1433

P1476

Sialylation-independent mechan ...... sing intravenous gammaglobulin

@en

P2093

Danila Leontyev

http://www.w3.org/2001/XMLSchema#string

Donald R Branch

http://www.w3.org/2001/XMLSchema#string

Sylvia Miescher

http://www.w3.org/2001/XMLSchema#string

Xue-Zhong Ma

http://www.w3.org/2001/XMLSchema#string

Yulia Katsman

http://www.w3.org/2001/XMLSchema#string

P2860

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy

A close look at human IgG sialylation and subclass distribution after lectin fractionation

Anti-inflammatory actions of intravenous immunoglobulin

Fc receptor blockade and immune thrombocytopenic purpura.

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.

P304

1799-1805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1537-2995.2011.03517.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221759077

http://www.w3.org/2001/XMLSchema#string

P698

22257295

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia